Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib  Parneet K. Cheema, MD, MBiotech, FRCPC  Journal.

Published byJasper Warren Modified over 5 years ago

Similar presentations

Presentation on theme: "A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib  Parneet K. Cheema, MD, MBiotech, FRCPC  Journal."— Presentation transcript:

1 A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib  Parneet K. Cheema, MD, MBiotech, FRCPC  Journal of Thoracic Oncology  Volume 12, Issue 12, Pages e200-e202 (December 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 (A and B) Computerized tomography at baseline before the start of afatinib therapy. (C and D) At week 12 after afatinib therapy. (D and E) At week 26 after afatinib therapy. Journal of Thoracic Oncology  , e200-e202DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib  Parneet K. Cheema, MD, MBiotech, FRCPC  Journal."

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages 1862-1863.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient  Hiromichi Shirasu, MD, Akira Ono, MD, Toshiaki.

Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient  Hiromichi Shirasu, MD, Akira Ono, MD, Toshiaki.
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
EGFR and KRAS Mutations in Triple-Mutated Lung Cancer

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma  Filippo Gustavo Dall’Olio, MD, Celeste.

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma  Filippo Gustavo Dall’Olio, MD, Celeste.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience  Ramsey Asmar, MD, Joshua R. Sonett, MD,

Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience  Ramsey Asmar, MD, Joshua R. Sonett, MD,
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib

Similar presentations

Ads by Google